Glycemic variability has become a major concern over the years as growing evidence is gathered on its detrimental impact on the risk of diabetes complications. Glycated hemoglobin, although ubiquitous in clinical practice, does not adequately summarize short-term glycemic variability. This gap may be addressed through the use of continuous glucose monitoring, which continuously estimates glycemia based on interstitial fluid glucose concentration. As the amount of collected data is substantial, variability of the glycemic pattern can be analyzed in context of its direction, periodicity, and amplitude. As freely available variability calculation tools are limited in number and complexity, the authors have devised a simple-to-use Web-based application, “GlyCulator,” allowing for rapid computation of glucose variability parameters from continuous glucose monitoring data.
SunJXuYSunSSunYWangX. Intermittent high glucose enhances cell proliferation and VEGF expression in retinal endothelial cells: The role of mitochondrial reactive oxygen species. Mol Cell Biochem.2010;343 (1–2): 27–35.
2.
SunJXuYDengHSunSDaiZSunY. Intermittent high glucose exacerbates the aberrant production of adiponectin and resistin through mitochondrial superoxide overproduction in adipocytes. J Mol Endocrinol.2010;44 (3): 179–85.
3.
KrinsleyJS. Glycemic variability in critical illness and the end of Chapter 1. Crit Care Med.2010;38 (4): 1206–8.
4.
MonnierLMasEGinetCMichelFVillonLCristolJ PColetteC. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA.2006;295 (14): 1681–7.
5.
HermanidesJVriesendorpTMBosmanRJZandstraDFHoekstraJBDevriesJH. Glucose variability is associated with intensive care unit mortality. Crit Care Med.2010;38 (3): 838–42.
6.
KilpatrickESRigbyASAtkinSL. A1C variability and the risk of microvascular complications in type 1 diabetes: Data from the Diabetes Control and Complications Trial. Diabetes Care.2008;31 (11): 2198–202.
7.
MonnierLColetteCOwensDR. Glycemic variability: The third component of the dysglycemia in diabetes. Is it important? How to measure it?J Diabetes Sci Technol.2008;2 (6): 1094–100.
RodbardDBaileyTJovanovicLZisserHKaplanRGargSK. Improved quality of glycemic control and reduced glycemic variability with use of continuous glucose monitoring. Diabetes Technol Ther.2009;11 (11): 717–23.
10.
RodbardD. Interpretation of continuous glucose monitoring data: Glycemic variability and quality of glycemic control. Diabetes Technol Ther.2009;11Suppl 1: S55–67.
11.
RodbardD. New and improved methods to characterize glycemic variability using continuous glucose monitoring. Diabetes Technol Ther.2009;11 (9): 551–65.
12.
ServiceFJMolnarGDRosevearJWAckermanEGatewoodLCTaylorWF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes.1970;19 (9): 644–55.
13.
WójcickiJM. Mathematical descriptions of the glucose control in diabetes therapy. Analysis of the Schlichtkrull “M”-value. Horm Metab Res.1995;27 (1): 1–5.
14.
WójcickiJM. “J”-index. A new proposition of the assessment of current glucose control in diabetic patients. Horm Metab Res.1995;27 (1): 41–2.
15.
MolnarGDTaylorWFHoMM. Day-to-day variation of continuously monitored glycaemia: A further measure of diabetic instability. Diabetologia.1972;8 (5): 342–8.
16.
McDonnellCMDonathSMVidmarSIWertherGACameronFJ. A novel approach to continuous glucose analysis utilizing glycemic variation. Diabetes Technol Ther.2005;7 (2): 253–63.
17.
FendlerWTucholskiKWalenciakLJarosz-ChobotPMlynarskiW. Fractal dimension analysis of continuous glucose monitoring data in screening for hypoglycemia-prone patients with type 1 diabetes — Preliminary report. 2nd Advanced Technologies and Treatments for Diabetes 2009.
18.
HiguchiT. Approach to an irregular time series on the basis of the fractal theory. Physica D.1988;31 (2): 277–83.
19.
MonnierLColetteCLeiterLCerielloAHanefeldMOwensDTajimaNTuomilethoJDavidsonJ, PGR Group. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care.2007;30 (1): 185–6.
20.
FendlerWMMlynarskiWM. Insulin therapy in very-low-birth-weight infants. N Engl J Med.2009;360 (5): 535–6.
21.
TakaoTIdeTYanagisawaHKikuchiMKawazuSMatsuyamaY. The effect of fasting plasma glucose variability on the risk of retinopathy in type 2 diabetic patients: Retrospective long-term follow-up. Diabetes Res Clin Pract.2010;89 (3): 296–302.
22.
KohnertKDAugsteinPZanderEHeinkePPetersonKFreyseEJHovorkaRSalzsiederE. Glycemic variability correlates strongly with postprandial beta-cell dysfunction in a segment of type 2 diabetic patients using oral hypoglycemic agents. Diabetes Care.2009;32 (6): 1058–62.
23.
KilpatrickESRigbyASAtkinSL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care.2006;29 (7): 1486–90.
24.
ServiceFJO'BrienPC. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care.2007;30 (1): 186–8.
25.
LeinungMThompsonSNardacciE. Benefts of continuous glucose monitor use in clinical practice. Endocr Pract.2010;16 (3): 371–5.
26.
KudvaYCBasuAJenkinsGDPonsGMVogelsangDARizzaRASmithSAIsleyWL. Glycemic variation and hypoglycemia in patients with well-controlled type 1 diabetes on a multiple daily insulin injection program with use of glargine and ultralente as basal insulin. Endocr Pract.2007;13 (3): 244–50.
